CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zura Bio Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zura Bio Ltd
4225 Executive Square, Suite - 600
Phone: (858) 247-0520p:858 247-0520 SAN DIEGO, CA  92037  United States Ticker: ZURAZURA
Business Summary
Zura Bio Limited is a multi-asset clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders. The Company is advancing immunology assets into phase II development programs, including ZB-168 and torudokimab. ZB-168 is an anti-interleukin-7 receptor subunit alpha (IL7Ra) inhibitor that has the potential to impact diseases driven by interleukin-7 (IL7) and thymic stromal lymphopoietin (TSLP) biological pathways. The Company focuses on developing a portfolio of therapeutic indications for ZB-168 that build on existing Phase Ib data in type 1 diabetes demonstrating a safety profile and biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (IL33), and is in the phase II clinical development stage.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board AmitMunshi 53 3/20/2023 3/20/2023
Chief Executive Officer, Director RobertLisicki 56 4/8/2024 1/8/2024
Interim Chief Financial Officer Verender S.Badial 50 1/1/2022
9 additional Officers and Directors records available in full report.

Business Names
Business Name
JATT
JATT.U
ZURA

General Information
Number of Employees: 14 (As of 12/31/2023)
Outstanding Shares: 43,593,678 (As of 3/26/2024)
Shareholders: 27
Stock Exchange: NASD
Email Address: info@zurabio.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024